logo
Thinking About Menopause Hormone Therapy? Start Here.

Thinking About Menopause Hormone Therapy? Start Here.

New York Times03-03-2025

At Dr. Monica Christmas's clinic these days, she sees two kinds of menopausal patients. The first, she said, is suffering from the symptoms associated with this life phase, but is also wary of hormone therapy because she's heard there are health risks associated with it.
The second kind of patient is almost the exact opposite: she may not have symptoms at all, but nonetheless is asking for hormones because she's heard they will make her healthier.
'We seem to like these extremes,' said Dr. Christmas, the director of the Menopause Program and Center for Women's Integrated Health at the University of Chicago.
Prescription data reflects a persistent anxiety around the health risks: In a study published in September, researchers found that only 5 percent of menopausal women used hormones in 2020 despite the fact that roughly 80 percent of women experience symptoms.
On the flip side, in the last few years, a growing number of social media influencers and celebrities, like Oprah Winfrey, have loudly endorsed hormone therapy, presenting it as a 'magic elixir,' Dr. Christmas said.
'Now there's this messaging that every woman who is menopausal should be on hormone therapy,' she said. But women need more clarity around what hormone therapy can and can't do. 'We've got to find our way back to the middle ground.'
What is menopausal hormone therapy?
Menopausal hormone therapy, or M.H.T., supplies some of the estrogen and progesterone lost in menopause. The Food and Drug Administration has approved dozens of types of therapies that have been shown to alleviate a narrow set of symptoms, including vasomotor symptoms — like hot flashes and night sweats — and genitourinary syndrome, which refers to painful sex, vaginal dryness and urinary tract infections. Hormone therapy can also be used to prevent postmenopausal bone loss.
There are two broad categories of hormone treatment: systemic, in which the hormones can affect the whole body, and local, which are applied just to the vagina. Systemic treatments contain either estrogen alone or a combination of estrogen and progestogen (a synthetic version of progesterone), and come in the form of a pill, patch, gel, cream, spray or vaginal ring. They tackle hot flashes and night sweats, and can prevent osteoporosis.
Systemic estrogen on its own can lead to the thickening of the uterine lining, which increases the risk of endometrial cancer, said Dr. Stephanie Faubion, director of the Mayo Clinic Center for Women's Health and medical director of the Menopause Society. Women who have had their uterus removed can safely use estrogen alone but others need to take some form of progestogen as well to counter its effects.
Local treatments applied to the vagina are lower-dose estrogen, and are mainly intended to address symptoms like vaginal dryness and pain with sex.
M.H.T. isn't approved to treat the dozens of other menopause symptoms, such as depression, anxiety, frozen shoulder, weight gain or hair loss, said Dr. Makeba Williams, a professor of obstetrics and gynecology at Washington University School of Medicine in St. Louis. But, the Menopause Society, which sets treatment guidelines, noted in its annual position statement that some patients who start hormone therapy do see small improvements in some of those symptoms too.
Earlier versions of F.D.A.- approved hormone therapy, which are still available today, contain what is called conjugated estrogen, derived from the urine of pregnant horses, while the products that are more commonly prescribed today (also approved by the F.D.A.) contain what is called bioidentical estrogen, which is derived from plant sources and has a more similar molecular structure to the hormones that the body creates. There are no quality studies comparing conjugated hormones head-to-head with bioidentical hormones, Dr. Faubion said, so we don't yet have a detailed understanding of how their risks and benefits differ.
Who is it for?
According to the Menopause Society, hormone therapy provides more effective relief and carries fewer risks for a woman who is suffering from vasomotor symptoms or genitourinary syndrome and is younger than 60 or less than a decade from their last period, compared to one who begins it later in life.
Hormone therapy is not recommended for women with a history of stroke, heart attacks, blood clots, liver disease, unexplained vaginal bleeding or estrogen-sensitive cancers, like those of the breast or uterus, as it might make those conditions worse.
What do we now know about the risks and benefits of hormone therapy?
The landmark Women's Health Initiative study, which was and still is the only long-term, large randomized trial of hormone therapy, was prematurely halted in 2002 because researchers found that the treatment elevated the risks for breast cancer and cardiovascular events. The study created widespread panic that led to women abandoning their treatments.
Since then, however, researchers have reanalyzed the data, and follow-up studies have found a more nuanced picture: Dose, delivery method and the age when therapy is initiated all make a big difference to the risks, Dr. Makeba said. And, in many cases, the benefits — including an improved quality of life — can outweigh the risks, she added.
Among symptomatic women younger than 60, the reanalyzed W.H.I. data showed that out of every 10,000 women using hormone therapy (specifically conjugated estrogen and a progestogen pill), there were six additional cases of breast cancer, though not breast cancer-related deaths, and five additional cases of coronary heart disease and stroke.
Meanwhile, the hormone therapy significantly reduced the risks of fractures, all-cause mortality and diabetes. For women taking estrogen alone, studies have consistently found that hormone therapy reduced breast cancer and cardiovascular risks — a finding that is still not fully understood.
Untreated menopause symptoms have been linked to long-term chronic health conditions later in life, including neurodegenerative diseases, though it is still unclear if the symptoms cause the poor health or if they are markers of another underlying problem.
The Menopause Society warns that for women who begin hormone therapy after 60, the risks for breast cancer and cardiovascular events increase.
'If you read the package labeling, it's going to say 'this may give you breast cancer, this may give you a heart attack' so there is that legacy of fear that still exists,' Dr. Makeba said. But 'we have to continue to educate about what are the real risks, the benefits, and for whom hormone therapy is appropriate and not.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FDA meeting gives window into gene therapy field's angst
FDA meeting gives window into gene therapy field's angst

Yahoo

time2 hours ago

  • Yahoo

FDA meeting gives window into gene therapy field's angst

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Anyone looking for evidence of genetic medicine's enormous promise need only read of KJ Muldoon. The 10-month-old infant headed home from a Philadelphia hospital this week, dressed in a celebratory cap and gown, after his life-threatening disease was successfully treated with a bespoke CRISPR therapy. While baby KJ is not cured, the treatment has stabilized his disease, a rare liver condition known as CSP1 deficiency, to such extent he's able to resume eating a normal diet. Doctors, who hurriedly designed and constructed KJ's custom therapy in a matter of months, have backed off supportive medications and hope he'll no longer need a liver transplant. 'Each year, 10 million babies are born with one of about 10,000 known rare genetic diseases, many of which are, in principle, now treatable with genetic medicines,' David Liu, a pioneering CRISPR scientist whose laboratory helped in KJ's treatment, said at a meeting hosted by the Food and Drug Administration Thursday. 'The opportunity created by this perfect storm moment in scientific, medical, regulatory and manufacturing innovation is to provide on-demand genetic treatments like KJ's at scale.' Yet Liu and 22 other gene therapy experts and advocates who attended Thursday's roundtable didn't travel to the regulator's headquarters in White Oak, Maryland to extol the field's advances. By and large, they came to warn of a crisis. There are now dozens of approved cell and gene therapies in the U.S., some of which offer near-curative potential for serious diseases like spinal muscular atrophy, sickle cell disease and acute lymphoblastic leukemia. However, the sector that's produced these therapies is struggling. Investors have soured on genetic medicine as developers struggle to prove they can profitably sell the complex and often hugely expensive treatments. Biotechnology companies are cutting research, laying off staff and, in some cases, shutting down. Large pharmaceutical firms are no longer willing to bet billions of dollars they can surmount the regulatory and reimbursement hurdles that stand in the way of many of these therapies. And academic labs, still bursting with promising new ideas for technologies like CRISPR, now fear their projects will wither on the vine. 'We estimate that over 100 rare disease gene therapy products that had reached clinical stage have been discontinued since 2023 — not because of treatment failure, but because of the risk of market failure,' said Terence Flotte, dean of the University of Massachusetts' T.H. Chan School of Medicine and president of the American Society of Cell and Gene Therapy. 'The scientific advances that we have witnessed are just nothing short of spectacular. It's not hyperbole,' said Crystal Mackall, a professor at Stanford University and founding director of the cancer cell therapy center there. 'Despite this unconditional scientific success, the field is really struggling to deliver these therapies to all patients who can benefit.' Their warnings found a receptive audience in FDA leadership. Commissioner Martin Makary and top official Vinay Prasad, who leads the office that oversees cell and gene therapies, were sympathetic to experts' arguments and pledged to help. 'We are going to continue the successes of the FDA in facilitating the regulatory process for these conditions and these products,' said Makary. 'We're also going to try to improve by creating more efficiencies.' Prasad, who in the past has criticized the FDA's accelerated approval of a gene therapy for Duchenne muscular dystrophy, showed support for flexible trial designs and endpoints when appropriate for the disease or treatment. He also noted the agency accepts that cell and gene therapies don't always comes with transformative potential. 'We understand that progress is not always made in a single leap,' he added. 'We will consider incremental steps forward, because those add up.' The assembled experts came with lists of possible solutions. Carl June, a famed immunologist and cell therapy researcher at the University of Pennsylvania, called for the U.S. to borrow from the two-tier regulatory system used in China, which allows for medical institutions to more rapidly start first-in-human trials under the supervision of local review boards. Don Kohn, a University of California, Los Angeles scientist who has developed gene therapies, asked the FDA to reduce the requirements for 'comparability' testing when companies transition production from academic to commercial settings. Others emphasized the importance of regulatory awards, like the priority review vouchers granted by the FDA to developers of certain therapies, who often sell them for needed capital. And many called for the agency to share more feedback and lessons learned from the applications they receive from industry. Behind all of their suggestions was a consistent concern: If regulators don't help solve the field's problems, the U.S. risks losing its leadership in developing the kinds of treatments that can cure diseases. 'If we don't adapt, the next generation of treatments will emerge abroad,' said June. 'The future of medicine with cell and gene therapy is at stake.' Their message seemed to be heard by Makary and Prasad, who noted that many of the issues raised are on their radar at FDA. Prasad, for instance, noted that they hope to redact and make available more internal documents to aid developers' understanding of what the FDA is looking for. 'This is not a horse and pony show to say we did this,' added Makary. 'This is an honest listening session.' Recommended Reading A bespoke CRISPR therapy suggests a blueprint for treating 'N-of-1' diseases

Alzheimer's blood test can accurately pick up early symptoms
Alzheimer's blood test can accurately pick up early symptoms

Yahoo

time6 hours ago

  • Yahoo

Alzheimer's blood test can accurately pick up early symptoms

A new blood test for Alzheimer's disease can accurately detect people with early symptoms, research suggests. Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. "This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting," he added. "While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed."

University Of Chicago Receives $21 Million Gift For Quantum Medicine
University Of Chicago Receives $21 Million Gift For Quantum Medicine

Forbes

time8 hours ago

  • Forbes

University Of Chicago Receives $21 Million Gift For Quantum Medicine

The University of Chicago is establishing a new center on quantum biology and medicine, thanks to a ... More $21 million gift by Thea Berggren. The University of Chicago has been given a $21 million private donation to establish a new center focused on merging quantum engineering with biology in the search for medical breakthroughs. The gift is from philanthropist Thea Berggren, who will be recognized by naming the the initiative the Berggren Center for Quantum Biology and Medicine. 'The establishment of the Berggren Center reflects a commitment to a powerful idea: that the deepest scientific insights often emerge when we bring distinct disciplines together in bold new ways,' said University of Chicago President Paul Alivisatos, in a news release. 'Combining quantum engineering with medicine, the work of the center stands to transform our understanding of health and disease. Housed within the University of Chicago Pritzker School of Molecular Engineering, the new center will be an interdisciplinary effort that brings together quantum physicists, engineers and clinicians. Those investigators will attempt "to harness the power of quantum engineering — capable of the most sensitive measurements known to science — to peer inside the human body in unprecedented ways." The goal is to develop new diagnostic tools and therapies that will be more finely tuned, offering the chance of personalized interventions for diseases like cancer. Those goals have recently come within reach because of advances in quantum science that enable very precise measurements of molecular and cellular activity within the human body. Through the use of quantum sensors, researchers can now observe biochemical activity that has not been detectable via prior imaging techniques, making it possible to translate quantum advances into clinical solutions. The center will be co-directed by Greg Engel, Professor in the Pritzker School of Molecular Engineering and the Department of Chemistry and Julian Solway, the Walter L. Palmer Distinguished Service Professor for Medicine and Pediatrics and the Director of the university's Institute for Translational Medicine. The pair have previously collaborated on research concerning the use of quantum imaging tools. 'Fusing quantum physics and medicine is no small feat, but it opens the door to tools and discoveries we never thought possible,' said Engel. 'This gift will help unite two very different scientific cultures in a common mission to improve human health.' The University of Chicago has become a global leader in quantum science and engineering, serving as the hub of the Chicago Quantum Exchange, a multi-partner international effort that is advancing the quantum future. The University also is part of a research and development ecosystem that includes one of the biggest quantum testbeds in the country; the first U.S. business incubator focused exclusively on quantum; and the Illinois Quantum and Microelectronics Park, which will be built on Chicago's South Side. The Berggren gift includes both endowed funds and money for current support. It will be used to fund several activities, including fellowships to train interdisciplinary scholars, technical development projects, and conferences brining together scholars in quantum biology and medicine. 'During a visit to the Atacama Desert, I engaged with astronomers from around the world, and all were inspired by how quantum mechanics is shaping the future, said Berggren in the university's announcement. 'That moment sparked a different question: What if we applied the same quantum principles to cellular physiology and pathology? The potential to transform medicine and how we understand and treat disease is extraordinary, and the University of Chicago is the ideal place to bring this vision to life.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store